论文部分内容阅读
[目的]观察黄芪注射液联合腹水回输治疗肝硬化顽固性腹水疗效。[方法]使用随机平行对照方法,将90例住院患者按病志号抽签简单随机分为三组。腹水回输组30例输液泵直接腹水回输,每24h换输血器,引流不畅时改变体位,回输至不能引流出腹水为止,拔出引流管,腹带加压数天,治疗后使用速尿保证尿量>1000m L。黄芪注射液组30例黄芪注射液30m L,常规消毒,左下腹或右下腹部注入腹腔,每隔48h重复注射1次。联合组30例黄芪注射液、腹水回输治疗同腹水回输组与黄芪注射液组。连续治疗14d为1疗程。观测临床症状、血浆白蛋白(ALB)、尿素氮(BUN)、肌酐(Cr),尿量、腹围、体重、不良反应。治疗1疗程,判定疗效。[结果]临床疗效联合组优于腹水回输组(P<0.01),黄芪注射液组与腹水回输组、联合组与黄芪注射液组组间比较无明显差异(P>0.05)。腹围、体重及血浆白蛋白含量各组均有改善(P<0.01),联合组、黄芪注射液组均优于腹水回输组(P<0.01),联合组优于黄芪注射液组(P<0.01)。[结论]黄芪注射液联合腹水回输治疗肝硬化顽固性腹水,疗效满意,无副作用,值得推广。
[Objective] To observe the therapeutic effect of astragalus injection combined with ascites reinfusion on refractory cirrhosis and ascites. [Methods] Using randomized parallel control method, 90 inpatients were randomly divided into three groups randomly according to the patient’s lot number. Ascites recovery group, 30 cases of infusion pump direct ascites back to transfusion every 24h for blood transfusions, poor drainage to change position, back to not drain out ascites, pulling out the drainage tube, abdominal pressure for days, after treatment Urine to ensure that urine output> 1000m L. Astragalus injection group 30 cases Astragalus injection 30m L, routine disinfection, left lower quadrant or right lower abdomen into the abdominal cavity, repeated injection once every 48h. Combined group of 30 cases Astragalus injection, ascites transfusion treatment of ascites reperfusion group and astragalus injection group. Continuous treatment 14d for a course of treatment. The clinical symptoms, ALB, BUN, Cr, urine output, abdominal circumference, body weight and adverse reactions were observed. Treatment of a course of treatment to determine the efficacy. [Result] The clinical curative effect was better than the ascites reinfusion group (P <0.01). There was no significant difference between Astragalus injection group and ascites reinfusion group, combination group and Astragalus injection group (P> 0.05). (P <0.01). The combined group and Astragalus injection group were better than the ascites transfusion group (P <0.01), and the combination group was better than Astragalus injection group (P <0.01) <0.01). [Conclusion] Combination of astragalus injection and ascites reinfusion in the treatment of refractory ascites caused by liver cirrhosis has satisfactory curative effect and no side effects, which deserves promotion.